Evidence map›Paper›PMID 31580415›Full record

ArticleBrain : a journal of neurology2019

Intrastriatal alpha-synuclein fibrils in monkeys: spreading, imaging and neuropathological changes.

Yaping Chu, Scott Muller, Adriana Tavares, Olivier Barret, David Alagille, John Seibyl, Gilles Tamagnan, Ken Marek, Kelvin C Luk, John Q Trojanowski and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Brain : a journal of neurology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed
10.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 110 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Disease-modifying, multidimensional efficacy of putaminal CaMolecular therapy : the journal of the American Society of Gene Therapy · 2025
    Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Neuronal SNCA transcription during Lewy body formation.Acta neuropathologica communications · 2023
    Article
  13. Article
  14. Article
  15. Review
  16. Monitoring α-synuclein aggregation.Neurobiology of disease · 2023
    Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Yaping ChuDepartment of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.
Scott MullerDepartment of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.
Adriana TavaresMolecular NeuroImaging, LLC New Haven, CT, USA.
Olivier BarretMolecular NeuroImaging, LLC New Haven, CT, USA.
David AlagilleMolecular NeuroImaging, LLC New Haven, CT, USA.
John SeibylMolecular NeuroImaging, LLC New Haven, CT, USA.
Gilles TamagnanMolecular NeuroImaging, LLC New Haven, CT, USA.
Ken MarekMolecular NeuroImaging, LLC New Haven, CT, USA.
Kelvin C LukDepartment of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
John Q TrojanowskiDepartment of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
Virginia M Y LeeDepartment of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
Jeffrey H KordowerDepartment of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.
Elucid Bioimaging · USRush University Medical Center · USUniversity of Pennsylvania · USInstitute for Neurodegenerative Disorders · US

Funding

Project IV "Tackling Heterogeneity of Cognitive Trajectory in LBD"U19AG062418 · NIA · UNIVERSITY OF PENNSYLVANIA · PI TROJANOWSKI, JOHN Q. · 2019 to 2023
$18.1M
NIA NIH HHS U19 AG062418
6 · The paper itself

Abstract

Several studies have demonstrated that intrastriatal injections of fibrillar α-synuclein in rodent brain induced a Parkinson's disease-like propagation of Lewy body pathology with significant nigrostriatal neurodegeneration. This study evaluated the pathological features when exogenous α-synuclein preformed fibrils were injected into the putamen of non-human primates. Eight cynomolgus monkeys received unilateral intraputamen injections of α-synuclein preformed fibrils and four monkeys received sham surgery. Monkeys were assessed with 123I-PE2I single-photon emission computerized tomography scans targeting the dopamine transprter at baseline, 3, 6, 9, 12, and 15 months. Imaging revealed a robust increase in dopamine transporter binding, an effect confirmed by port-mortem immunohistochemical analyses, suggesting that upregulation of dopamine transporter occurs as part of an early pathological process. Histochemistry and immunohistochemistry revealed that α-synuclein preformed fibrils injections into the putamen induced intraneuronal inclusions positive for phosphorylated α-synuclein in ipsilateral substantia nigra and adjacent to the injection site. α-Synuclein inclusions were thioflavin-S-positive suggesting that the inclusions induced by α-synuclein preformed fibrils exhibited pathological properties similar to amyloid-like Lewy body pathology in Parkinson's disease brains. The α-synuclein preformed fibrils resulted in Lewy pathology in the ipsilateral substantia nigra with significant reduction (-29.30%) of dopaminergic neurons as compared with controls. Nigral neurons with α-synuclein inclusions exhibited a phenotypic downregulation of the dopamine markers tyrosine hydroxylase and Nurr1. Taken together, our findings demonstrate that α-synuclein preformed fibrils induce a synucleinopathy in non-human primates with authentic Lewy pathology and nigrostriatal changes indicative of early Parkinson's disease.

Indexed as

alpha-SynucleinAnimalsCell CountDopamine Plasma Membrane Transport ProteinsDopaminergic NeuronsImmunohistochemistryLewy BodiesMacaca fascicularisMicroinjectionsNeostriatumNuclear Receptor Subfamily 4, Group A, Member 2PutamenSubstantia NigraSynucleinopathiesTomography, Emission-Computed, Single-PhotonTyrosine 3-Monooxygenasealpha-SynucleinDopamine Plasma Membrane Transport ProteinsNuclear Receptor Subfamily 4, Group A, Member 2Tyrosine 3-MonooxygenaseLewy bodiesneurodegenerationnigrostriatal systempropagationα-synuclein

Identifiers

PMID31580415
PMCPMC7962904
OpenAlexW2977443709

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.